<DOC>
	<DOCNO>NCT00006413</DOCNO>
	<brief_summary>This study investigate safety effectiveness experimental stem cell transplant procedure treat mastocytosis-a disease abnormal mast cell growth . Patients often feel faint , skin problem , joint bone pain , low blood count enlarge liver , spleen lymph node . As yet , cure mastocytosis , treatment aim control symptom . Stem cell cell produce bone marrow mature different blood components-white cell , red cell platelet . Transplantation allogeneic ( donate ) stem cell mainstay therapy form leukemia . Patients first receive intensive chemotherapy radiation rid body cancer cell . This `` conditioning '' follow transplantation donate stem cell generate new , healthy bone marrow . In addition produce new bone marrow , donate cell also fight residual tumor cell might remain body . This call `` graft-versus-tumor '' effect . This study examine whether stem cell transplant healthy donor similarly target destroy mast cell `` graft-versus-mast cell '' effect . Also , try reduce harmful side effect chemotherapy radiation , study use lower dose chemotherapy radiation . Patients advance mastocytosis 10 80 year old may eligible study . They test HLA type match sibling undergo medical history , physical examination several test determine eligibility study . Participants undergo apheresis collect lymphocytes ( type white blood cell ) immune function test . In procedure , blood drawn needle arm , similar donate unit blood . The lymphocyte separate collect cell separator machine , rest blood return needle arm . Patients also central venous line ( flexible plastic tube ) place upper chest lead vein . This line remain place throughout transplant recovery period use transfuse blood component , administer medicine , infuse donated stem cell , draw blood test . Patients begin condition cyclophosphamide , start 7 day transplant , fludarabine , start 5 day transplant , prevent rejection donate cell . From 1 3 day chemotherapy complete , stem cell transfused central venous line . Also , 4 day transplantation 3 month procedure , patient receive cyclosporine mycophenolate mofetil-drugs help prevent rejection donate cell attack donor cell patient 's cell ( call graft-versus-host disease ) . Patients stay hospital 20 30 day transplant . After discharge , continue take antibiotic , cyclosporine mycophenolate mofetil home . If mastocytosis progress , cyclosporine mycophenolate mofetil taper 4 week . If mastocytosis persists , patient may receive additional transfusion donor lymphocytes help kill mast cell . Patients ' progress follow weekly twice weekly 3 month , 6 , 12 , 18 , 24 , 30 , 36 , 48 60 month transplant , twice year various test , treatment examination .</brief_summary>
	<brief_title>Stem Cell Transplantation Treat Systemic Mastocytosis</brief_title>
	<detailed_description>Mastocytosis disease characterize excessive number mast cell skin , bone marrow internal organ liver , spleen lymph node . Its genesis appear relate somatic mutation c-kit , receptor mast cell growth factor . Although patient present indolent form disease , approximately one-third patient associate hematologic disorder myeloproliferative state myelodysplastic syndrome . Patients advance form disease , include associate hematologic disorder poorer prognosis indolent disease . There treatment know cure improve natural course mastocytosis . Since mast cell arise bone marrow CD34+ progenitor , bone marrow transplantation may offer hope cure . In protocol , propose treat patient advance form mastocytosis allogeneic stem cell transplant HLA-identical sibling , use low intensity non-myeloablative regimen . This approach advantage decrease transplant-related toxicity allow adequate immunosuppression establish stem cell lymphocyte engraftment . Donor derive CD4 CD8 lymphocytes , important kill leukemic cell mount `` graft versus leukemia '' effect , useful elimination aberrant mast cell progenitor , `` graft-versus-mast cell effect '' . This mechanism may particularly relevant mastocytosis point mutation c-kit may constitute antigenically distinct T-cell target recognition engraft donor cell . The primary end point study regression mastocytosis . The secondary end point engraftment , hematologic response , degree donor-host chimerism , incidence severity acute chronic GVHD , transplant relate morbidity mortality , relapse , disease free survival , overall survival .</detailed_description>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<criteria>INCLUSION CRITERIA : PATIENT Ages great equal 2 80 . Wt great 40 kg . Patients systemic mastocytosis proven bone marrow biopsy one following : Category I disease poor prognosis secondary extensive bone marrow involvement mast cell ( i.e . great 50 percent bone marrow cavity replace mast cell ) evidence bone marrow failure state define presence one follow great equal 2 month : Neutrophil count le 500/ mm3 . Platelet count less 20,000/mm3 . Dependency transfusion RBC platelet . Category II disease associate hematologic disorder : Myelodysplastic syndrome . Myeloproliferative state except essential thrombocytosis polycythemia vera . Increased blast peripheral blood bone marrow great 10 percent . Bone marrow failure state describe . Category III disease enlarge peripheral lymph node histopathological evidence replacement entire lymph node architecture mast cell and/or accompany peripheral eosinophilia . We also consider aggressive systemic mastocytosis local tissue invasion category III disease . Category IV disease mast cell leukemia , characterize presence malignant mast cell peripheral blood , constitute great 10 percent nucleate cell . No major organ dysfunction preclude transplantation . DLCO great equal 65 percent predict . Left ventricular ejection fraction great equal 40 % . ECOG performance status 0 1 . Life expectancy 3 month . HLAidentical sibling available donor . Patients parent ( ) /responsible guardian ( ) must able comprehend investigational nature study willing sign inform consent . INCLUSION CRITERIA : DONOR HLA identical family donor , ( HLA identical ) . Weight great equal 18 kg . Age less equal 80 year old . Informed consent give . EXCLUSION CRITERIA : PATIENT ( Any follow ) Pregnant lactate Age le 2 age great 80 year . Weight le equal 40 kg . ECOG performance status 2 . Psychiatric disorder mental deficiency severe make compliance BMT treatment unlikely , make informed consent impossible . Major anticipated illness organ failure incompatible survival PBSC transplant . DLCO le 65 percent predict . Left ventricular ejection fraction le 40 % . Baseline GFR le 50ml/min : measure calculate follow formula : GFR = { ( 140age ) x body weight kg } /72 x serum creatinine ( female , multiply 0.85 ) . Serum bilirubin great 4 mg/dl , transaminases great 5 time upper limit normal . Other malignant disease liable relapse progress within 5 year . Life expectancy le 3 month . EXCLUSION CRITERIA : DONOR ( Any follow ) Pregnant lactating . Donor unfit receive GCSF undergo apheresis ( Uncontrolled hypertension , history congestive heart failure unstable angina , thrombocytopenia ) . HIV positive . Donors positive HBV , HCV HTLV1 may use riskbenefit ratio consider acceptable patient investigator . Weight great 18 kg . Age great 2 less 80 year .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 14, 2006</verification_date>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Non-Myeloablative Bone Marrow Transplantation</keyword>
	<keyword>Engraftment</keyword>
	<keyword>Graft-versus-host Disease</keyword>
	<keyword>Graft-Versus-Leukemia</keyword>
	<keyword>Graft-Versus-Mast Cell</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Donor Apheresis</keyword>
	<keyword>Mast Cells</keyword>
</DOC>